ClinicalTrials.gg
Status unknownNCT03264794Updated Aug 29, 2017

the Clinical Trial of Gefitinib(Non - Small Cell Lung Cancer)

A Phase 4 interventional study of Gefitinib Tab (CTTQ),First medication;Gefitinib Tab (CTTQ),From the 8th day of trial and Gefitinib tablets (Yi Ruisha),First medication in Non-small Cell Lung Cancer, sponsored by Jiangsu Famous Medical Technology Co., Ltd.. Status unknown. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-08-29.

Sponsored by Jiangsu Famous Medical Technology Co., Ltd. · Phase 4, Interventional, and Treatment

How we know

The sponsor has not verified this record recently (last verified Jan 2017), so the status shown — last known as Not yet recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
100
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

  1. Gefitinib CTTQ production gefitinib and erlotinib sheet AstraZeneca imatinib sheet (trade name: Iressa ®) comparison, human pharmacokinetics and relative bioavailability of comparative studies which examine people in vivo pharmacokinetic behavior, provide the basis for clinical use.
  2. Evaluation CTTQ gefitinib imatinib sheet production efficacy and safety of Chinese patients with locally advanced or metastatic non-small cell lung cancer.
02

Conditions studied

  • Non-small Cell Lung Cancer
03

In context

Carcinoma, Non-Small-Cell Lung

7,638 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,840 are open to participants now.

This study's planned enrollment of 100 is above the median of 62 across 6,031 interventional studies indexed under Carcinoma, Non-Small-Cell Lung.

Browse Carcinoma, Non-Small-Cell Lung studies →

Lead sponsor

Jiangsu Famous Medical Technology Co., Ltd. is the lead sponsor of 20 studies on the registry; 7 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patients volunteered to participate in this study, signed ;
  2. ≥18 years old; PS score: 0 \~ 1; expected survival period of more than 3 months;
  3. patients with locally advanced or non-small cell lung cancer diagnosed by histology or cytology, who can not receive radical surgery or radiotherapy; patients with (according to criteria);
  4. Detection of EGFR-positive exon 19 deletion or exon 21 (L858R) mutation was performed by providing a detectable specimen (tissue or cancerous pleural effusion) prior to enrollment;
  5. The main organ function within 7 days before treatment, meet the following criteria:

(1) blood routine examination criteria (14 days without blood transfusion): A) ≥ 90g / L; B) neutrophil absolute ≥ 1.5 × 109 / L; C) ≥80 × 109 / L (2) biochemical tests to meet the following criteria: A) total ≤ 1.5 times the (ULN); B) and aspartate aminotransferase AST ≤ 2.5ULN, such as liver metastasis, ALT and AST ≤ 5ULN; C) serum creatinine ≤ 1.5ULN or ≥ 60ml / min; (3) Doppler ultrasound evaluation: (LVEF) ≥ normal low (50%).

6.Women of childbearing age should agree that measures (such as intrauterine devices, birth control pills or condoms) must be used within the study period and within 6 months after the end of the study; serum or urine pregnancy test is negative within 7 days prior to enrollment, And must be non-lactating patients; men should agree to patients who have contraceptive use during the study period and six months after the end of the study period.

Exclusion criteria

Exclusion Criteria:

  1. patients who have previously used EGFR-TKI drugs;
  2. small cell lung cancer (including small cell carcinoma and non-small cell carcinoma mixed lung cancer);
  3. central type, with empty lung squamous cell carcinoma, or with non-small cell lung cancer with hemoptysis (> 50 ml / day) 4.5 years or at the same time with other , cured cervical carcinoma in situ, non-melanoma skin cancer and superficial bladder tumor except [Ta (non-invasive tumor), Tis (carcinoma in situ ) And T1 (tumor infiltrating basement membrane)];

5.Whole-body antitumor therapy was planned within 4 weeks prior to randomization or during the course of this study, including cytotoxic therapy, signal transduction inhibitors, immunotherapy (or use of mitogen at 6 weeks prior to administration of the test drug) C); 6.patients with symptomatic or unstable ; 7.patients with any severe and / or uncontrolled disease, including: A) cirrhosis, acute or active hepatitis; B) history of immunodeficiency, including -positive or other acquired, congenital immunodeficiency disease, or history of organ transplantation; C) patients with seizures and who need treatment; 8.active or uncontrollable serious infection (≥CTC AE Level 2 infection); 9.with a history of mental illness and can not quit or have mental disorders; 10.participated in other anti-tumor drug clinical trials within four weeks; 11.According to the judge's judgment, there is an impact on the absorption of oral drugs or serious harm to the safety of patients is not suitable for participation in the study of the situation.

Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
100 participants (estimated)

Study arms

  • Experimental
    trial group

    Gefitinib tablets (CTTQ),First medication.From the 8th day of the experiment, treated with Gefitinib Tab(CTTQ)

    Drug: Gefitinib Tab (CTTQ),First medication;Gefitinib Tab (CTTQ),From the 8th day of trial · Drug: Gefitinib Tab 250 MG(CTTQ),From the 8th day of trial.

  • Active comparator
    control group

    Gefitinib tablets (Yi Ruisha),First medication.From the 8th day of the experiment, treated with Gefitinib Tab(CTTQ)

    Drug: Gefitinib tablets (Yi Ruisha),First medication · Drug: Gefitinib Tab 250 MG(CTTQ),From the 8th day of trial.

Interventions

  • DrugGefitinib Tab (CTTQ),First medication;Gefitinib Tab (CTTQ),From the 8th day of trial

    Gefitinib Tab (CTTQ),First medication,250mg;

  • DrugGefitinibStudies of GefitinibGefitinib pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Gefitinib tablets (Yi Ruisha),First medication,250mg;

  • DrugGefitinib Tab 250 MG(CTTQ),From the 8th day of trial.

    From the 8th day of the experiment, two groups of subjects were treated with Gefitinib(CTTQ)

06

What researchers measure

Primary outcomes

  1. Gefitinib plasma concentration

    After the use of gefitinib to reach the highest plasma concentration

    Time frame: 0hour before administration and 1, 2, 3, 4, 5, 6, 7, 8,9,13,24,48,72,120,168 16 hour time points after administration

  2. Tmax time

    Taking the time required for the concentration of gefitinib to reach the peak

    Time frame: 0hour before administration and 1, 2, 3, 4, 5, 6, 7, 8,9,13,24,48,72,120,168 16 hour time points after administration

  3. AUC0-t

    The area between the axis of the coordinate and the time drug concentration curve

    Time frame: 0hour before administration and 1, 2, 3, 4, 5, 6, 7, 8,9,13,24,48,72,120,168 16 hour time points after administration

  4. t 1/2

    The time required for gefitinib to decrease by half the highest concentration in plasma

    Time frame: 0hour before administration and 1, 2, 3, 4, 5, 6, 7, 8,9,13,24,48,72,120,168 16 hour time points after administration

  5. F

    Gefitinib absorbs the relative amount of blood into the cycle

    Time frame: 0hour before administration and 1, 2, 3, 4, 5, 6, 7, 8,9,13,24,48,72,120,168 16 hour time points after administration

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Aug 2017; primary completion for Dec 2021, 52 months later.

Of 43 phase 4 interventional studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 48. This study's planned 52 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 3, 2017
First posted
Aug 29, 2017
StartEst.
Aug 2017
Primary completionEst.
Dec 2021
CompletionEst.
Jun 2022
Last update
Aug 29, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 29, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03264794
Lead sponsor
Jiangsu Famous Medical Technology Co., Ltd.
Responsible party
Sponsor
First posted
Aug 29, 2017
Start date
Aug 2017 (estimated)
Primary completion
Dec 2021 (estimated)
Completion
Jun 2022 (estimated)
Last update
Aug 29, 2017

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Jan 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion